CompletedNot Applicable

Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia

United States14 participantsStarted 2011-12

Plain-language summary

The purpose of this study is to test whether the addition of oral flecainide to standard therapy will reduce ventricular ectopy on exercise test compared to placebo plus standard therapy in patients with Catecholaminergic Polymorphic Ventricular Tachycardia.

Who can participate

Age range5 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Clinical diagnosis of CPVT, based on:
✓. Functioning ICD in place
✓. On stable dose of standard therapy defined as the maximal tolerated dose of beta-blocker and may include a calcium channel blocker

Exclusion criteria

✕. Females who are pregnant or plan to be pregnant during the study period
✕. Children \< 5 years of age
✕. Patients unable to perform treadmill exercise
✕. Patients with significant structural heart disease
✕. Patients with features consistent with Andersen-Tawil syndrome A. Periodic paralysis or unexplained weakness B. Dysmorphic facies C. Known KCNJ2 mutation
✕. Patients with known hypersensitivity to flecainide
✕. Patients on amiodarone
✕. Patients not expected to comply with follow-up

What they're measuring

Number of Patients With Ventricular Ectopy or VT During Exercise Treadmill Testing

Timeframe: 3 months

Trial details

NCT IDNCT01117454

SponsorVanderbilt University Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2015-12

Results submitted2017-02-22

View on ClinicalTrials.gov More Catecholaminergic Polymorphic Ventricular Tachycardia trials